Bharat Rasayan Ltd
Bharat Rasayan Ltd is engaged in manufacturing Technical Grade Pesticides and Intermediates used in the agro-chemical industry. It was incorporated in 1989.[1]
- Market Cap ₹ 3,723 Cr.
- Current Price ₹ 8,959
- High / Low ₹ 14,284 / 8,798
- Stock P/E 26.4
- Book Value ₹ 2,719
- Dividend Yield 0.02 %
- ROCE 16.6 %
- ROE 13.3 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of -0.67% over past five years.
- Company has a low return on equity of 12.8% over last 3 years.
- Dividend payout has been low at 0.53% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 989 | 1,213 | 1,091 | 1,301 | 1,234 | 1,044 | 1,173 | |
| 802 | 983 | 852 | 1,050 | 1,043 | 926 | 998 | |
| Operating Profit | 188 | 230 | 240 | 250 | 191 | 118 | 175 |
| OPM % | 19% | 19% | 22% | 19% | 15% | 11% | 15% |
| 1 | 14 | 6 | 16 | 15 | 35 | 42 | |
| Interest | 16 | 16 | 4 | 7 | 6 | 3 | 5 |
| Depreciation | 17 | 22 | 26 | 25 | 26 | 26 | 27 |
| Profit before tax | 155 | 205 | 215 | 234 | 174 | 123 | 185 |
| Tax % | 28% | 23% | 24% | 25% | 28% | 23% | 24% |
| 112 | 158 | 164 | 176 | 125 | 96 | 141 | |
| EPS in Rs | 262.48 | 371.03 | 385.69 | 423.51 | 299.88 | 229.85 | 339.13 |
| Dividend Payout % | 1% | 0% | 0% | 0% | 0% | 1% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -3% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | -7% |
| TTM: | 50% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 5% |
| 3 Years: | -5% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 13% |
| Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves | 405 | 560 | 723 | 766 | 889 | 984 | 1,126 |
| 247 | 94 | 58 | 174 | 28 | 80 | 85 | |
| 100 | 94 | 122 | 142 | 152 | 129 | 193 | |
| Total Liabilities | 756 | 752 | 908 | 1,086 | 1,074 | 1,197 | 1,408 |
| 150 | 203 | 191 | 228 | 225 | 230 | 230 | |
| CWIP | 35 | 18 | 18 | 11 | 11 | 6 | 15 |
| Investments | 0 | 9 | 150 | 43 | 67 | 143 | 298 |
| 570 | 522 | 549 | 803 | 771 | 818 | 865 | |
| Total Assets | 756 | 752 | 908 | 1,086 | 1,074 | 1,197 | 1,408 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| -52 | 263 | 170 | -65 | 213 | 41 | 172 | |
| -46 | -53 | -149 | 64 | -43 | -76 | -157 | |
| 102 | -169 | -40 | -25 | -152 | 49 | -1 | |
| Net Cash Flow | 4 | 40 | -19 | -26 | 18 | 14 | 14 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 103 | 75 | 99 | 130 | 96 | 138 | 130 |
| Inventory Days | 112 | 70 | 90 | 120 | 141 | 135 | 136 |
| Days Payable | 24 | 17 | 33 | 30 | 33 | 37 | 67 |
| Cash Conversion Cycle | 191 | 128 | 156 | 221 | 204 | 236 | 200 |
| Working Capital Days | 173 | 116 | 134 | 185 | 173 | 227 | 268 |
| ROCE % | 34% | 31% | 28% | 20% | 13% | 17% |
Documents
Announcements
-
Board recommends Final Dividend
29 May - Bharat Rasayan reports FY25 audited results, recommends 15% dividend, re-appoints Executive Director.
-
Standalone & Consolidated Financial Results, Auditors Report for March 31, 2025
28 May - Bharat Rasayan reports FY25 audited results, recommends 15% dividend, and re-appoints Executive Director.
-
Integrated Filing (Financial)
14 Feb - Approval of standalone and consolidated financial results.
- Standalone & Consolidated Financial Results, Limited Review Report for December 31, 2024 14 Feb
-
Board Meeting Intimation for Results & Closure of Trading Window
21 Jan - Board meeting scheduled to approve financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from web
-
Financial Year 2020
from bse
-
Financial Year 2019
from web
-
Financial Year 2018
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Product Portfolio
The company has a leading market position in many technical and intermediate products, including Lambda Cyhalothrin Technical, Metaphenoxy Benzaldehyde, Metribuzine Technical, Thiamethoxam (Insecticides), Fipronil (Insecticides), etc. It has also added new products like Fluxametamide, Tolfenpyrad Technical, Diuron Technical, etc. Top 10 products account for 66% of total sales. [1]